Business Segments Provectus Biopharmaceuticals, Inc.
Stocks
PVCT
US74373P1084
Biotechnology & Medical Research
|
Real-time
OTC Markets
15:37:28 2026-06-02 EDT
|
5-day change | 1st Jan Change | ||
| 0.0620 USD | -7.32% |
|
+13.76% | +10.91% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Clinical Stage Biotechnology | - | 989K | 558K | 617K | 336K | |||||
Total Assets | 3.51M | 2.04M | 1.45M | 1.01M | 698K | |||||
Interest Expense | -962K | -164K | -216K | -239K | -210K | |||||
CAPEX | - | - | - | - | - | |||||
EBT | -5.54M | -3.55M | -3.1M | -4.76M | -5.43M | |||||
D&A | 12.86K | 10.9K | 8.92K | 7.16K | 1.86K | |||||
Operating Income | -4.67M | -3.43M | -2.9M | -4.53M | -5.29M | |||||
Net Income | -5.54M | -3.55M | -3.1M | -4.76M | -5.43M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | 989K | 558K | 617K | 336K | |||||
Total Assets | 3.51M | 2.04M | 1.45M | 1.01M | 698K | |||||
Interest Expense | -962K | -164K | -216K | -239K | -210K | |||||
D&A | 12.86K | 10.9K | 8.92K | 7.16K | 1.86K | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | -5.54M | -3.55M | -3.1M | -4.76M | -5.43M | |||||
EBT | -5.54M | -3.55M | -3.1M | -4.76M | -5.43M | |||||
Operating Income | -4.67M | -3.43M | -2.9M | -4.53M | -5.29M |
- Stock Market
- Stocks
- PVCT Stock
- Financials Provectus Biopharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
